In this poster we evaluate TMB testing availability, adoption, and methods used to assess US NSCLC patients utilizing our Diagnostic Network for Precision Medicine (DXRX®) data platform to access Real-world data from over 100,000 patients diagnosed with NSCLC from 2019 to 2020.
Poster #ST42 Overview:
Tumor Mutation Burden measures patient tumor mutation quantity. High TMB status clinically correlates with better Immune Checkpoint Inhibitor (ICI) therapy outcomes. Several methods and definitions exist to measure patient TMB status. Today, guidelines classify TMB as an emerging biomarker, and acknowledge no consensus exists on how to test. However, an approved therapy with a targeted Next-Generation Sequencing (NGS) panel-based Companion Diagnostic (CDx) provides a TMB High status definition linked to a single ICI.
In poster #ST42 Diaceutics evaluate TMB testing availability, adoption, and methods used to assess US NSCLC patients using DXRX® data platform to access Real-world data from 106,076 patients diagnosed with NSCLC from Q1 2019 to Q3 2020.